Skip to main content

Advertisement

Table 2 Efficacy of a single dose of an oral chewable tablet containing sarolaner, moxidectin and pyrantel pamoate against induced ascarid infections in dogs

From: Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced ascarid infections in dogs

StudyAscarid/Target stage (isolate origin)Treatment groupanGeometric mean worm countEfficacy compared to placebo
% EfficacyTest statistic
1Toxocara canis/immature adults (L5) (USA)Placebo833.3
SAR + MOX + PYR81.695.2t(14) = 6.32
P < 0.0001
SAR + MOX88.474.7t(14) = 3.16
P = 0.0070
2Toxocara canis/immature adults (L5) (EU)Placebo815.2
SAR + MOX + PYR80.397.9t(14) = 5.61
P = 0.0008
3Toxocara canis/adults (USA)Placebo811.5
SAR + MOX + PYR80.199.2t(26) = 7.99
P < 0.0001
SAR87.336.7t(26) = 1.35
P = 0.1869
MOX80.892.8t(26) = 6.29
P < 0.0001
PYR80100t(26) = 8.27
P < 0.0001
4Toxocara canis/adults (EU)Placebo824.4
SAR + MOX + PYR80.697.3t(7) = 10.40
P = 0.0001
5Toxascaris leonina/adults (EU)Placebo825.0
SAR + MOX + PYR82.689.7t(7) = 7.98
P < 0.0001
6Toxascaris leonina/adults (EU)Placebo820.1
SAR + MOX + PYR80.199.6t(7) = 17. 02
P < 0.0001
  1. aSingle oral administration providing minimum dosages of 1.2 mg/kg sarolaner (SAR), 24 µg/kg moxidectin (MOX) and 5 mg/kg pyrantel pamoate (PYR)